AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9%

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9%
Thu, 30 May

AUROBINDO PHARMA has announced its results for the quarter ended March 2019. Here is a detailed performance review of the same:

AUROBINDO PHARMA Quarterly Financials

No. of Mths
Qtr. Ending
3
Mar-18*
3
Dec-18*
3
Mar-19*
QoQ ChangeYoY Change
Net SalesRs m40,49152,69752,9220.4%30.7%
Other incomeRs m438639323-49.5%-26.4%
TurnoverRs m40,92953,33553,245-0.2%30.1%
ExpensesRs m32,61041,83342,3471.2%29.9%
Gross profitRs m7,88410,61310,215-3.8%29.6%
DepreciationRs m1,5661,6311,86614.4%19.1%
InterestRs m2474775015.1%102.6%
Profit before taxRs m6,5099,1448,170-10.7%25.5%
TaxRs m1,2242,0482,31112.9%88.8%
Profit after taxRs m5,2857,0965,859-17.4%10.9%
Gross profit margin%19.520.119.3
Effective tax rate%18.822.428.3
Net profit margin%12.913.311.0
* Results Consolidated
Interim results exclude extraordinary / exceptional items
Source: Company Reports, Regulatory Filings, Equitymaster


Year-on-Year Performance:
  • The company's operating income during the quarter grew 30.7% on a year-on-year (YoY) basis. The expenses were up by 29.9% YoY during the same period.
  • The company's operating profit increased by 29.6% YoY during the quarter. Consequently, operating profit margins remained same and stood at 19.3% in 4QFY19.
  • Depreciation charges increased by 19.1% and finance costs increased by 102.6% YoY, respectively.
  • Other income declined by 26.4% YoY during the quarter.
  • Net profit for the quarter increased by 10.9% YoY. Net profit margins during the quarter declined from 12.9% in 4QFY18 to 11.0% in 4QFY19.
Quarter-on-Quarter Performance:
  • The company's operating income during the quarter grew 0.4% on a quarter-on-quarter (QoQ) basis. The expenses were up by 1.2% QoQ during the same period.
  • The company's operating profit declined by 3.8% QoQ during the quarter. Consequently, operating profit margins witnessed a decline and stood at 19.3% in 4QFY19 as against 20.1% in 3QFY18.
  • Net profit for the quarter declined by 17.4% QoQ, while net profit margins declined from 13.3% in 3QFY18 to 11.0% in 4QFY19.

To see how AUROBINDO PHARMA has performed over the last eight quarters, please visit here.

AUROBINDO PHARMA Share Price Performance

Over the last one year, AUROBINDO PHARMA share price has moved up from Rs 565.8 to Rs 691.3, registering a Gain of Rs 125.5 or around 22.2%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 13,339.1 (up 0.2%). Over the last one year it has moved up from 13,111.9 to 13,339.1, a gain of 227 points (up 1.7%).

Overall, the S&P BSE SENSEX is up 13.6% over the year.

Current Valuations

At the current price of Rs 691.3, the price to earnings (P/E) ratio of AUROBINDO PHARMA stands at 17.1 times its trailing twelve months earnings, while its price to book value (P/BV) ratio stands at 3.5 times.

Equitymaster requests your view! Post a comment on "AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9%". Click here!

  

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

It's Time to Book Profits(Fast Profits Daily)

Nov 27, 2020

In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.

How the New Margins Will Impact You(Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

Create Wealth for Yourself in India's Drone Revolution(Profit Hunter)

Nov 27, 2020

The Chinese drone market is 14 times that of India's. Billions may flow into Indian drone companies too. Don't miss out on this wealth creating opportunity.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Dec 4, 2020 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS